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Abstract
Background: Molecular screening for BRCA1 and BRCA2 mutations is now an established component of risk
evaluation and management of familial breast cancer. Features of hereditary breast cancer include an early age-of-
onset and over-representation of the 'triple-negative' phenotype (negative for estrogen-receptor, progesterone-
receptor and HER2). The decision to offer genetic testing to a breast cancer patient is usually based on her family
history, but in the absence of a family history of cancer, some women may qualify for testing based on the age-of-
onset and/or the pathologic features of the breast cancer.
Methods: We studied 54 women who were diagnosed with high-grade, triple-negative invasive breast cancer at
or before age 40. These women were selected for study because they had little or no family history of breast or
ovarian cancer and they did not qualify for genetic testing using conventional family history criteria. BRCA1
screening was performed using a combination of fluorescent multiplexed-PCR analysis, BRCA1 exon-13 6 kb
duplication screening, the protein truncation test (PTT) and fluorescent multiplexed denaturing gradient gel
electrophoresis (DGGE). All coding exons of BRCA1 were screened. The two large exons of BRCA2 were also
screened using PTT. All mutations were confirmed with direct sequencing.
Results: Five deleterious BRCA1 mutations and one deleterious BRCA2 mutation were identified in the 54
patients with early-onset, triple-negative breast cancer (11%).
Conclusion: Women with early-onset triple-negative breast cancer are candidates for genetic testing for
BRCA1, even in the absence of a family history of breast or ovarian cancer.
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The two major contributors to hereditary breast cancer are
the cancer susceptibility genes BRCA1 and BRCA2 [1].
Genetic testing for BRCA1 and BRCA2 mutations has been
established throughout North America and much of
Europe. Not all women are candidates for testing – in gen-
eral, testing is offered to a woman who has a probability
of ten percent or greater for being positive for a mutation.
An exception is made for women from particular ethnic
backgrounds, such as Ashkenazi Jewish, French-Canadian
or Polish women; in these groups, a small number of
founder mutations is responsible for the majority of
hereditary cancers [2-4]. For women in these groups, test-
ing is inexpensive and eligibility criteria can be relaxed.
However, in a mixed ethnic population, such as is found
in most of the United States and Canada, testing involves
the complete screening of the coding sequences of the two
genes. In order to maximize both the efficiency of testing
and the public health impact of a genetic screening pro-
gram, many centers offer screening to women when the
prior probability of finding a mutation is ten percent or
greater. Several mathematical models such as BRCAPRO
and BOADICEA can be used to estimate the prior proba-
bility of having a mutation [5,6]. These models consider
age-of-onset and family history of cancer. Certain charac-
teristics of the breast cancer can also be used to help pre-
dict the presence of a mutation. BRCA1-associated cancers
are typically high-grade and are 'triple negative'; i.e. are
negative for estrogen-receptor (ER), progesterone-receptor
(PR) and HER2 expression [7,8]. The majority of triple-
negative cancers exhibit the basal phenotype, i.e., they
also express basal type cytokeratins (keratin 5 or keratin 6)
or epidermal growth factor receptor (EGFR) (80% to 90%
of triple-negative cancers are basal phenotype). The pro-
portion of BRCA1-associated cancers that are of the 'basal
phenotype' has been estimated to be 88% by Foulkes et al
[7] and 57% by Lakhani et al. [8]. Furthermore, the pro-
portion of BRCA1-associated cancers that are ER-negative
(one of the component features) diminishes with increas-
ing age-of-onset. Foulkes et al found that 81% of BRCA1-
associated breast cancers diagnosed before age 45 were
ER-negative, compared to 62% of cancers in women diag-
nosed after age 65 [9]. In contrast to the high proportion
among BRCA1-associated breast cancer, only about 15%
of all women with breast cancer have triple-negative can-
cers [10]. Therefore, this subgroup of women is expected
to be enriched for BRCA1-mutation carriers. In this study,
we estimate the proportion of BRCA1 mutation carriers
among women diagnosed at age 40 or younger with tri-
ple-negative breast cancer, without a significant family
history of cancer.
Methods
Cases for study were identified from two hospital systems
(the Palmetto Health Richland/Baptist Hospitals, Colum-
bia SC and the Cancer Genetics Clinic of Ohio State Uni-
versity, Columbus) and through genetic counselors
affiliated with the National Society of Genetic Counselors
Cancer Special Interest Group. Women diagnosed with
breast cancer at age 40 years and younger and who did not
have a significant family history of breast or ovarian can-
cer were chosen for study. We also excluded patients of
Ashkenazi Jewish heritage because they would be eligible
for routine genetic testing (founder mutations) in any
cancer center and because we do not expect to find non-
founder mutations in this population. A total of 97
patients were submitted for evaluation, of which 58 were
eligible for the study. Women were excluded if there was
insufficient documentation of triple-negative status to
include them in the study (n = 32) or if they had a positive
family history of cancer (n = 6) or if the age of diagnosis
was missing (n = 1). Twenty-eight patients were submitted
from the Palmetto Health Richland and Baptist Hospitals.
Women were identified though the Palmetto Health Can-
cer Directory or at presentation to a weekly breast cancer
conference. A woman was eligible if her medical records
indicated that her breast carcinoma was grade III and was
negative for ER, PR and HER2. HER2 overexpression was
defined as moderate to strong staining that totally encir-
cles the cell membrane (2+ or 3+). Women with a cancer
diagnosis within three years of study initiation were
invited to participate. These 14 women were mostly from
South Carolina. Nineteen patients were submitted from
Ohio State University: these women were identified from
a database of 1300 breast cancer patients who had been
accrued to a separate research protocol. They were diag-
nosed with breast cancer at one of three hospitals in the
Columbus, OH area, between May 2003 and August
2006. Informative cases were chosen for being high-grade,
triple-negative breast cancers diagnosed at age 40 and
younger. Twenty-five patients were recruited through the
National Society of Genetic Counselors Cancer Special
Interest Group. An email notification was posted on the
society list-serve (NSGC Cancer-SIG). This list-serve is
read by approximately 300 genetic counselors who spe-
cialize in cancer. The notice solicited breast cancer
patients who diagnosed at age 40 or younger, had no can-
cer family history and who were 'triple-negative'. Twenty-
two counselors submitted patients. All patients accrued
through the NSGC Cancer-SIG were interviewed by a
genetic counselor and a three-generation pedigree was
drawn. The study was approved by the institutional review
board (IRB) of the Palmetto Health Richland/Baptist Hos-
pitals IRB (Columbia, SC 29201) and of the Women's
College Research Institute.
Laboratory methods
DNA was extracted from whole blood lymphocytes using
standard methodology. We evaluated the entire coding
sequence of BRCA1 and the large exons 10 and 11 ofPage 2 of 5
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mon BRCA1 alterations (185delAG and 5382insC) and
one BRCA2 alteration (6174delT) by rapid fluorescent
multiplexed-PCR analysis, FMPA [11]. All patients were
screened for the BRCA1 exon-13 6 kb duplication [12].
BRCA1 exon 11, and BRCA2 exons 10 and 11 were
screened using protein truncation test, PTT (TNT™ rabbit
reticulocyte lysate system, Promega, and [35S]methio-
nine/cysteine, New England Nuclear). All other BRCA1
exons, with the exception of exons 1a/b and 4, were also
scanned by fluorescent multiplexed denaturing gradient
gel electrophoresis, DGGE [13]. The first 2 kb at the begin-
ning and the end of exon 11 were also included in the
DGGE analysis, as were all exon-intron boundaries. All
variants identified by either PTT or DGGE were confirmed
by direct sequencing. These methods are expected to iden-
tify almost all BRCA1 mutations and 70% of BRCA2
mutations which are identifiable through direct sequenc-
ing.
Results
A total of 58 women with triple-negative cancer was eligi-
ble for testing, but four samples were of poor quality and
these patients were excluded, leaving 54 patients. The
mean age of cancer diagnosis was 34.7 years (range 24 to
40 years). None of the patients had a significant family
history as defined by the American Society of Clinical
Oncology [14]. No patient had a past history of ovarian
cancer and no patient had a first-degree relative with ovar-
ian cancer or breast cancer. No patient had a family his-
tory of male breast cancer. Two patients had bilateral
breast cancer; in both instances the triple-negative tumour
was the first tumour to be diagnosed and neither had a
family history of breast or ovarian cancer.
Six deleterious mutations were identified in the 54
patients (11%); five in BRCA1 and one in BRCA2 (table
1). The 5382insC mutation was seen on two occasions
and the four other mutations were seen one time each. All
mutations were protein-truncating. A BRCA1 mutation
was identified in 5 of 34 white patients (15%) and none
of 20 patients of other ethnicities (ten African-American,
six Hispanic, two Asian, two mixed). The single BRCA2
mutation was found in an African-American woman
(4936delAG). A mutation was found in 0 of 11 women
diagnosed with breast cancer at or before age 30 and in 6
of 43 women (14%) diagnosed between ages 31 and 40.
Nine additional BRCA1 variants of no, or unknown, clin-
ical significance were also identified (table 2).
Discussion
These data support the position that early-onset triple-
negative breast cancer is an indicator that can be used to
help to identify candidates for BRCA1 mutation testing.
Our study is relatively small (54 patients) but we confirm
similar observations made by others. To date, no single
study has been large or definitive, and therefore it is
important to consider the results of all studies in aggre-
gate. Lidereau et al found that 6 of 70 women (9%) with
breast cancer diagnosed at age 35 or below, unselected for
family history, carried a BRCA1 mutation [15]. However,
the proportion with mutations was 29% (4 of 14) for
those with ER-negative, high-grade tumours, compared to
only 4% (2 of 56) among women with other tumour types
(odds ratio = 11; p = 0.007). Among women in our study
who were diagnosed before the age of 35, the mutation
prevalence was 8.3%. In a study of 254 white women
from the UK, diagnosed with breast cancer before age 36,
a germline BRCA1 or BRCA2 mutation was identified in
only 6% (ref 16). Of the 15 women with germline muta-
tions, only one had a family history of breast or ovarian
cancer. In this early study, the study sample was not sub-
divided by ER-status or other factors.
A number of studies suggest that breast cancers associated
with BRCA1 mutations are likely to be triple-negative and
the majority of these are also the basal phenotype [7,8,17-
19]. Basal-like tumours express certain cytokeratins char-
acteristic of the 'basal' layer myoepithelial cells lining the
terminal duct lobular unit (namely cytokeratins 5, 6, 14
and 17) [20]. Basal-like tumours are usually high-grade,
exhibit comedeonecrosis, pushing borders and an inflam-
matory lymphocytic infiltrate.
Other studies included women who were selected for fam-
ily history or ethnic group. Chang et al. studied women
with familial breast cancer (at least one first-degree rela-
tive with either breast or ovarian cancer) diagnosed before
age 45 [17]. They found that 6 of 24 (25%) patients with
an ER-negative, high-grade tumour had a germline BRCA1
Table 1: Deleterious mutations identified among fifty-four triple-negative cases:
Gene Exon Mutation Mutation Type Age of Onset Ethnic Group
BRCA1 11 1294del40 Deletion 35 Caucasian
BRCA1 11 2800delA Deletion 32 Irish/Scottish
BRCA1 15 4731C>T Nonsense 36 Caucasian
BRCA1 20 5382insC Insertion 38 Caucasian
BRCA1 20 5382insC Insertion 39 Caucasian
BRCA2 11 4936delAG Deletion 39 African AmericanPage 3 of 5
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women with triple-negative breast cancer had a BRCA1
mutation (24%), but these included women with a strong
family history of breast cancer [18]. Foulkes et al. found
that of 24% of 72 Ashkenazi Jewish patients diagnosed
before age 65 with high grade, ER-negative, HER2-nega-
tive breast cancers had a germline BRCA1 mutation [7].
However, the frequency of mutations is known to be high
in this group. Given that all Ashkenazi Jewish women
with breast cancer are candidates for BRCA mutation test-
ing, we excluded this group from the present study.
Our study has several limitations. Our subjects were
derived from various sources, including a population-
based series of cases (Ohio), and from a US hospital
(North Carolina) and from women who presented for
genetic risk assessment to various clinics across the coun-
try. The determination of grade, ER, PR and HER2 status
was based on review of pathology report and there was no
central pathology review (however, this situation accu-
rately reflects actual clinical practise). The purpose of this
study was to estimate the prevalence of BRCA1 mutations
and the entire BRCA2 gene was not screened. However,
the triple-negative phenotype is not characteristic of
BRCA2-associated breast cancers. We expect that the
majority of BRCA mutations diagnosed in the triple-nega-
tive, family history negative subgroup cancers will be
BRCA1. In most situations, genetic counsellors will offer
to test for both genes, and if a woman is insured, testing
for both genes will be covered. However, for women who
do not have full coverage, or in countries where resources
are limited, some may wish to test triple-negative patients
for BRCA1 only.
All five BRCA1 mutations were seen in white women
between the ages of 31 and 40; in this subgroup the muta-
tion prevalence was 17%. It is interesting that no muta-
tion was identified in a woman diagnosed before age 30;
however this subgroup was small and it is in not clear if
this is a chance finding. Further studies will be useful in
determining if there are other genetic markers of very
early-onset breast cancer.
The criteria used to offer genetic testing to a patient varies
from center to center, but in general, testing is usually
offered to a woman if the probability of finding a muta-
tion exceeds ten percent [14]. Most guidelines for select-
ing patients rely on family history, but in many centers,
genetic testing is routinely offered to all women diag-
nosed with breast cancer under the age of 40. In the
absence of a family history, fewer than ten percent of
patients in this group are expected to carry a BRCA muta-
tion.
Conclusion
Our study indicates that young women with a high-grade
triple-negative cancer and no family history of cancer may
be candidates for genetic testing. However, women with
other histologic forms of cancer (e.g. ER-positive or HER2-
positive) and with no family history are unlikely to carry
a mutation.
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